Qinhua Liu
Overview
Explore the profile of Qinhua Liu including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
25
Citations
117
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Xiong W, Yu Y, Sun C, Du J, Cai Z, Wang Z, et al.
Haematologica
. 2023 Sep;
109(2):666-670.
PMID: 37706332
No abstract available.
2.
Zong C, Xiao Y, Shao T, Chiou J, Wu A, Huang Z, et al.
Food Res Int
. 2023 Sep;
172:113104.
PMID: 37689873
The objectives of this study were to explore the β-carotene-producing bacteria and ascertain the main factors affecting β-carotene content via investigating the effects of various additives on β-carotene content, bacterial...
3.
Zhuang Z, Tian Y, Shi L, Zou D, Feng R, Tian W, et al.
Front Oncol
. 2023 May;
13:1028571.
PMID: 37152063
Maintenance treatment is a pivotal part in the whole process management of multiple myeloma (MM), which further deepens response and improves survival. However, evidence of maintenance in non-transplant MM patients...
4.
Li L, Wang L, Liu Q, Wu Z, Zhang Y, Xia R
Front Oncol
. 2023 Jan;
12:954345.
PMID: 36644638
Background: CD22 single and CD19/CD22 bispecific targeted chimeric antigen receptor T (CAR-T) cell therapy are promising immunotherapy modalities for the treatment of hematologic malignancies. The aim of this study was...
5.
Sang W, Ma Y, Wang X, Ma Y, Shen Z, Gu W, et al.
Am J Surg Pathol
. 2022 Aug;
46(11):1533-1544.
PMID: 36006771
De novo CD5 + diffuse large B-cell lymphoma (DLBCL) has poor survival in the era of immunochemotherapy. Accurate gene-based typing and prognostic stratification can enhance the development of effective individualized...
6.
iRGD-modified exosomes-delivered BCL6 siRNA inhibit the progression of diffuse large B-cell lymphoma
Liu Q, Dai G, Wu Y, Zhang M, Yang M, Wang X, et al.
Front Oncol
. 2022 Aug;
12:822805.
PMID: 35982974
Clinical applications of siRNA therapeutics have been limited by the immunogenicity of the siRNA and low efficiency of siRNA delivery to target cells. Recently, evidence have shown that exosomes, endogenous...
7.
Ma S, Zhang B, Lu T, Li D, Li T, Shen Z, et al.
Cancer
. 2022 Aug;
128(19):3487-3494.
PMID: 35932292
Background: CD5-positive diffuse large B-cell lymphoma (DLBCL) is a clinically rare subtype of DLBCL with aggressive clinical manifestations and a poor prognosis. It has been demonstrated that the prognostic nutritional...
8.
Zong C, Wu Q, Shao T, Dong Z, Liu Q
J Sci Food Agric
. 2022 Jul;
103(1):221-232.
PMID: 35857393
Background: The use of alfalfa is a promising response to the increasing demand for squalene. Ensiling could enhance the squalene content of fresh alfalfa and silage. To investigate and exploit...
9.
Shen Z, Yingliang Jin , Sun Q, Zhang S, Chen X, Hu L, et al.
Front Immunol
. 2022 Mar;
13:829878.
PMID: 35251016
Hemophagocytic lymphohistiocytosis (HLH) is an immune disorder with rapid progression and poor survival. Individual treatment strategy is restricted, due to the absence of precise stratification criteria. In this multicenter retrospective...
10.
Shen Z, Zhang S, Zhang M, Hu L, Sun Q, He C, et al.
Front Oncol
. 2022 Feb;
11:823079.
PMID: 35127536
Diffuse large B-cell lymphoma (DLBCL) is a highly heterogeneous non-Hodgkin lymphoma, and the prognosis of DLBCL patients is widely affected by multivariables. Clinical-factors-based prognostic systems stratify the prognosis of DLBCL...